Epanova

Phase 3Small molecule

AstraZeneca

Epanova is one of 108 small molecule programs targeting Pancreatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreatitisActive, not recruiting

Type 2 DiabetesActive, not recruiting

HypertriglyceridemiaActive, not recruiting

PancreatitisPhase 1

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

HypertriglyceridemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Epanova

AstraZeneca

Phase 3

1 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Glargine

Eli Lilly

Preclinical

8 7

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 10

Forxiga

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPA1 trial

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01208961·54 enrolled

Crohn's Disease1 trial

EPANOVA in Crohn's Disease, Study 1

Completed·TTillotts Pharma AG·Phase 3·NCT00613197·384 enrolled

Type 2 Diabetes1 trial

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02370537·490 enrolled

Hypertriglyceridemia1 trial

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02104817·13,078 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Completed·TTillotts Pharma AG·Phase 3·NCT00074542·364 enrolled

3 more indications

Pancreatitis1 trial

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02189252·30 enrolled

Concentration1 trial

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02359045·137 enrolled

Unspecified2 trials

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02009865·379 enrolled

A Ph 1 Study of Epanova® in Healthy Chineses

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03574142·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Epanova. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epanova compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epanova. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Epanova

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPA1 trial

Crohn's Disease1 trial

Type 2 Diabetes1 trial

Hypertriglyceridemia1 trial

Efficacy and Safety1 trial

Pancreatitis1 trial

Concentration1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News